Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.
Published version of a preprint
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhibitor resistance were enrolled; 17 of 39 patients (44%) had tumor shrinkage, with 5 patients (13%) achieving partial response. Pharmacodynamic studies confirmed marked Sym004-induced EGFR downmodulation. MET gene amplification emerged in 1 patient during Sym004 treatment, and a partial response was seen in a patient with EGFRS492R mutation that is predictive of cetuximab resistance. Significance: Potent EGFR downmodulation with Sym004 in patients with metastatic colorectal cancer and acquired resistance to cetuximab/panitumumab translates into significant antitumor activity and validates the preclinical hypothesis that a proportion of tumors remains dependent on EGFR signaling. Further clinical development and expanded correlative analyses of response patterns with secondary RAS/EGFR mutations are warranted. Cancer Discov; 5(6);598–609. ©2015 AACR. See related commentary by Stintzing and Heinemann, p. 578 This article is highlighted in the In This Issue feature, p. 565
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have shown that Sym004 could effectively inhibit cells stimulated by EGFR ligands and overcome cetuximab resistance mediated by EGFR ECD mutations in CRC [18,147].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [18]
In the citing paper
“Sym004, a novel 1:1 mixture of two nonoverlapping anti-EGFR mAbs, showed significant advantages of abrogating EGFR ligand-induced phosphorylation and suppressing downstream signalling of all individual EGFR mutants both in cetuximab-resistant cell lines and in a tumour xenograft model [23, 71].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [71]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“Acknowledging the limited number of patients treated with Sym004, it remains noteworthy that the response rate seen in this trial was similar to that assessed in previous phase III studies with cetuximab and panitumumab monotherapy in EGFR treatment–naïve patients with metastatic colorectal cancer (5, 6).”
ResultWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“, wild-type KRAS and NRAS) population (4).”
BackgroundSelf-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 1×
“Preclinical findings point to conservation of EGFR dependency of tumors that progressed upon cetuximab or panitumumab therapy (7), even in the case of acquired mutations in RAS genes (8, 9), with EGFR ligands playing a central role in autocrine and paracrine resistance networks (10–12).”
BackgroundDouillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 2×
“Dose expansion Dose escalation (N = 20) 12 mg/kg (N = 29) 9 mg/kg (N = 13) Number of patients (%) Any adverse event 19 (95) 29 (100) 13 (100) Any grade ≥3 adverse event 11 (55) 28 (97) 13 (100) Any serious adverse event 10 (50) 16 (55) 10 (77) Drug-related fatal adverse events 0 (0) 1 (3) 0 (0)”
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 3×
“Solid epithelial tumorsa Metastatic colorectal cancer Dose escalation 12 mg/kg 9 mg/kg Full analysis set 20 (100) 29 (100) 13 (100) Age (years) Median 61 63 68 Min–max 35–81 35–84 52–79 Sex (N, %) Female 13 (65) 14 (48) 6 (46) Male 7 (35) 15 (52) 7 (54) Previous treatment for mCRC (N, %) Bevacizumab NA 18 (62) 5 (39)…”
BackgroundSadanandam, A., Lyssiotis, C. A., Homicsko, K., Collisson, E. A., Gibb, W. J., Wullschleger, S., Ostos, L. C. G., Lannon, W. A., Grotzinger, C., Del Rio, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3175 · Cited by 960 · cited 1×
“Solid epithelial tumorsa Metastatic colorectal cancer Dose escalation 12 mg/kg 9 mg/kg Full analysis set 20 (100) 29 (100) 13 (100) Age (years) Median 61 63 68 Min–max 35–81 35–84 52–79 Sex (N, %) Female 13 (65) 14 (48) 6 (46) Male 7 (35) 15 (52) 7 (54) Previous treatment for mCRC (N, %) Bevacizumab NA 18 (62) 5 (39)…”
Background
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021
Self-citationNext generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
Metadata
- Authors
- Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., Hansen, U. H., Hald, R., Pedersen, M. W., Kragh, M., Horak, I. D., Braun, S., Van Cutsem, E., Tolcher, A. W., & Tabernero, J.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- South Texas Accelerated Research Therapeutics (US)
- 4Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (HUVR, CSIC, Universidad de Sevilla), Center affiliated to the RTICC (ISCiii), Sevilla, Spain.
- 5Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
- Consejo Superior de Investigaciones Científicas (ES)
- Universitat de València (ES)
- Radboud University Medical Center (NL)
- 6Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Symphogen (Denmark) (DK)
- 8Digestive Oncology Department, University Hospitals Leuven and KULeuven, Leuven, Belgium.
- Corresponding author
- Tabernero, Josep
- ORCID
- Venue
- Cancer Discovery
- Published
- 2015-06-01
- Volume
- 5
- Issue
- 6
- Pages
- 598-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2130584549
- Cited by
- 77
- References
- 28
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 13 · 2017: 13 · 2016: 15 · 2015: 9
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- European Commission
- Symphogen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- metastatic colorectal cancer, EGFR inhibitor resistance, cetuximab resistance, MET amplification, skin toxicity, hypomagnesemia, dose-limiting toxicity, tumor shrinkage, RAS mutations
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Gene Amplification, Humans, Ligands, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Treatment Outcome, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, Class I Phosphatidylinositol 3-Kinases, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-14-1432
- The paper
- Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., Hansen, U. H., Hald, R., Pedersen, M. W., Kragh, M., Horak, I. D., Braun, S., Van Cutsem, E., Tolcher, A. W., & Tabernero, J. (2015). Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-14-1432
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.